Attachment B-1a
`Worldwide Net Sales of Competitor Drugs
`
`Brand
`
`Januvia
`
`Janumet
`
`Total
`
`Drug
`
`Sitagliptin
`
`Vildagliptin
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`Total
`
`
`
`43$
`
`
`
`668$
`
`
`
`1,397$
`
`
`
`1,922$
`
`
`
`2,385$
`
`
`
`3,324$
`
`
`
`4,086$
`
`
`
`4,004$
`
`
`
`3,931$
`
`
`
`3,863$
`
`
`
`25,623$
`
`Total
`2009 - 2015
`
`23,515$
`
`n/a
`
`
`
`86$
`
`
`
`351$
`
`
`
`658$
`
`
`
`954$
`
`
`
`1,363$
`
`
`
`1,659$
`
`
`
`1,829$
`
`
`
`2,071$
`
`
`
`2,151$
`
`
`
`11,123$
`
`
`
`10,685$
`
`
`
`43$
`
`
`
`754$
`
`
`
`1,748$
`
`
`
`2,580$
`
`
`
`3,339$
`
`
`
`4,687$
`
`
`
`5,745$
`
`
`
`5,833$
`
`
`
`6,002$
`
`
`
`6,014$
`
`
`
`36,745$
`
`
`
`34,200$
`
`
`
`5,723$
`
`Galvus/Eucreas
`(Non-US only)
`
`US
`
`Non-US
`
`Total
`
`n/a
`
`n/a
`
`n/a
`
`n/a
`
`Saxagliptin
`
`n/a
`
`
`
`43$
`
`
`
`181$
`
`
`
`391$
`
`
`
`677$
`
`
`
`910$
`
`
`
`1,200$
`
`
`
`1,224$
`
`
`
`1,140$
`
`
`
`5,766$
`
`n/a
`
`n/a
`
`n/a
`
`n/a
`
`n/a
`
`n/a
`
`
`
`22$
`
`
`
`119$
`
`
`
`339$
`
`
`
`516$
`
`
`
`591$
`
`
`
`481$
`
`
`
`420$
`
`
`
`2,488$
`
`
`
`2,488$
`
`
`
`2$
`
`
`
`39$
`
`
`
`134$
`
`
`
`193$
`
`
`
`286$
`
`
`
`339$
`
`
`
`366$
`
`
`
`1,359$
`
`
`
`1,359$
`
`
`
`24$
`
`
`
`158$
`
`
`
`473$
`
`
`
`709$
`
`
`
`877$
`
`
`
`820$
`
`
`
`786$
`
`
`
`3,847$
`
`
`
`3,847$
`
`Notes and sources:
`Figures are in millions of USD.
`Sitagliptin: EX1052 at 8, 59; EX1054 at 7, 54; EX1056 at 6, 50; EX1059 at 3, 43, 68, 132; see also EX1053 EX1055 EX1057-EX1059.
`Vildagliptin: EX1045 at 266; EX1046 at 140; EX1047 at 137; EX1048 at 114; EX1049 at 147; EX1050 at 113, 115; EX1051 at 189; see also EX1044.
`Saxagliptin: EX 2113 at 35, EX 2113 at 35, EX 2113 at 35, EX 2115 at 35, EX 2115 at 35, EX 2004 at 203, EX 2108 at 210, 228.
`
`Attachment B-1a
`Page 1 of 14
`
`Mylan et al. v. AstraZeneca
`IPR2015-01340
`
`MYLAN - EXHIBIT 1062B
`
`

`
`Attachment B-1b
`
`Chart of Sitagliptin, Vildagliptin, and Saxagliptin Worldwide Net Sales
`
`$7.000
`
`$6.000
`.2a
`
`$5,000
`
`$4,000
`
`3,000
`‘ T
`
`$2,000
`
`’”°° j.._.
`
`5-
`
`2009
`
`2010
`
`2011
`
`2012
`
`Year
`
`2013
`
`2014
`
`2015
`
`Notes and soumes:
`
`Attachment B-la
`
`Tsitagliptin :Vi|dag|iptin jSaxag|iptin
`
`

`
`Attachment B-1c
`
`Chart of Vildagliptin and Saxagliptin Net Sales
`
`$1,400
`
`$1’
`
`$1,000
`
`E’E’
`
`$200
`
`5-
`
`2009
`
`Notes and sources:
`
`Attachment B-la
`
`{L
`
`2010
`
`2011
`
`2012
`
`Year
`
`2013
`
`2014
`
`2015
`
`TVi|dag|iptin (Non—US)
`
`isaxagliptin (Total)
`
`jsaxagliptin (Non—US)
`
`

`
`Attachment B-2
`Prescription Shares Among DDP4 Inhibitors
`
`Product
`
`Measure
`
`Prescriptions
`(thousands)
`
`Prescription
`share among
`DDP4 inhibitors
`
`Onglyza
`Kombiglyze XR
`Januvia Family
`Tradjenta Family
`Nesina Family
`Total
`Onglyza
`Kombiglyze XR
`Januvia Family
`Tradjenta Family
`Nesina Family
`Total
`
`2009
`(Jul - Dec)
`33 9
`
`
`-
`
`4,640 2
`-
`
`
`-
`
`4,674.1
`0.7%
`0.0%
`99.3%
`0.0%
`0.0%
`100.0%
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`678 2
`
`
`0.1
`
`9,847.3
`
`-
`
`-
`
`10,525.6
`6.4%
`0.0%
`93.6%
`0.0%
`0.0%
`100.0%
`
`1,480.0
`
`
`372.3
`
`10,986.5
`
`98.7
`
`-
`
`12,937.6
`11.4%
`2.9%
`84.9%
`0.8%
`0.0%
`100.0%
`
`1,909.5
`
`
`899.5
`
`12,633.6
`
`654.1
`
`-
`
`16,096.8
`11.9%
`5.6%
`78.5%
`4.1%
`0.0%
`100.0%
`
`1,816.3
`
`
`971.7
`
`12,650.4
`
`1,435 9
`
`15.6
`
`16,889 9
`10.8%
`5.8%
`74.9%
`8.5%
`0.1%
`100.0%
`
`1,740.9
`
`
`927 2
`
`12,979.3
`
`1,879.1
`
`49.1
`
`17,575.6
`9.9%
`5.3%
`73.8%
`10.7%
`0.3%
`100.0%
`
`2015
`(Jan - Jul)
`
`897 2
`
`491.5
`
`7,703.5
`
`1,447 9
`
`43 2
`
`10,583.3
`8.5%
`4.6%
`72.8%
`13.7%
`0.4%
`100.0%
`
`Total
`(2009-2015)
`
`8,556.0
`
`3,662.2
`
`71,440.9
`
`5,515.7
`
`108.0
`
`89,282.8
`9.6%
`4.1%
`80.0%
`6.2%
`0.1%
`100.0%
`
`Total
`(2011-2015)
`7,843.9
`
`
`3,662.2
`
`56,953.4
`5,515.7
`
`
`108.0
`
`74,083 2
`10.6%
`4.9%
`76.9%
`7.4%
`0.1%
`100.0%
`
`Notes and sources:
`EX2117: IMS Health, National Prescriptions Audit.
`
`Attachment B-2
`Page 4 of 14
`
`

`
`Attachment B-3
`DPP-4 Inhibitor Prescriptions by Drug, 2006-2015
`
`Notes and sources:
`EX1035: AstraZeneca AB v. Aurobindo, et al. , PTX2344 (Hofmann Report).
`Figures from 2009 to 2015 have been verified using EX2117: IMS Health, National Prescriptions Audit.
`I understand that Dr. Meyer does not disagree with any calculations from the Hofmann Report:
`EX1029: AstraZeneca AB v. Aurobindo, et al. , Trial Transcript 442:4-13.
`
`Attachment B-3
`Page 5 of 14
`
`

`
`Attachment B-4
`Marketing Spend as a Share of Gross Sales
`
`Product
`
`Measure
`
`Promotional
`Spending
`(millions)
`
`US Sales
`(millions)
`
`Marketing Share
`Sales
`
`Onglyza
`Kombiglyze XR
`Total
`Onglyza
`Kombiglyze XR
`Total gross sales
`Total net sales
`Onglyza
`Kombiglyze XR
`Total gross sales
`Total net sales
`
`2009
`(Jul - Dec)
`44.1$
`
`
`-$
`
`44.1$
`
`13.3$
`
`-$
`
`13.3$
`
`22.0$
`330.7%
`n/a
`330.7%
`200.4%
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`128.6$
`
`
`0.5$
`
`129.1$
`
`150.5$
`
`0.3$
`
`150.8$
`
`119.0$
`85.5%
`163.3%
`85.6%
`108.5%
`
`85.5$
`
`
`54.1$
`
`139.5$
`
`361.1$
`
`73.0$
`
`434.1$
`
`339.0$
`23.7%
`74.1%
`32.1%
`41.2%
`
`65.8$
`
`
`38 2$
`
`104.0$
`
`481.8$
`
`200.0$
`
`681.8$
`
`516.0$
`13.7%
`19.1%
`15.3%
`20.2%
`
`55.0$
`
`
`33.1$
`
`88.1$
`
`524.8$
`
`253.1$
`
`778.0$
`
`591.0$
`10.5%
`13.1%
`11.3%
`14.9%
`
`35.7$
`
`
`11.1$
`
`46.8$
`
`579.0$
`
`288.1$
`
`867.1$
`
`481.0$
`6 2%
`3.8%
`5.4%
`9.7%
`
`2015
`(Jan - Jul)
`
`14.6$
`5.0$
`
`
`19.6$
`
`338.5$
`
`180.0$
`
`518.5$
`
`420.0$
`4.3%
`2.8%
`3.8%
`4.7%
`
`Total
`(2009-2015)
`
`429.3$
`
`141 9$
`
`571.3$
`
`2,449.0$
`
`994.5$
`
`3,443.5$
`
`2,488.0$
`17.5%
`14.3%
`16.6%
`23.0%
`
`Total
`(2011-2015)
`256.7$
`
`
`141.4$
`
`398.1$
`
`2,285.2$
`
`994 2$
`
`3,279.4$
`
`2,347.0$
`11.2%
`14.2%
`12.1%
`17.0%
`
`Notes and sources:
`Attachment B-1a
`EX2118: IMS Health, National Sales Perspective.
`EX2119: IMS Health, Integrated Promotional Services.
`
`Attachment B-4
`Page 6 of 14
`
`

`
`Attachment B-5
`
`Prescriptions of Onglyza vs. Januvia, 2009-2015
`
`900.000
`
`:: ' '
`600.000
`A
`
`4
`
`500.000
`
`400.000
`
`300.000
`
`200.000
`
`100.000
`
`1
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`Year
`
`éonglyza
`
`élanuvia
`
`Notes and soumes:
`
`EX2117: IMS Health, National Prescriptions Audit.
`
`

`
`Attachment B-6
`
`Prescriptions of Onglyza vs. Tradjenta, 2009-2015
`
`250.000
`
`200.000
`
`150.000
`
`100.000
`
`50.000
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`Year
`
`ionglyza
`
`:Tradjenta
`
`Notes and sources:
`
`EX2117: IMS Health, National Prescriptions Audit.
`
`

`
`Attachment B-7
`
`Prescriptions of Kombiglyze XR vs. Junamet, 2009-2015
`
`400,000
`
`350,000
`
`300,000
`W, ‘V
`W, —I'''
`
`r
`
`150,000
`
`100,000
`
`50,000
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`Year
`
`éKombig|yze XR
`
`ilanumet + Janumet XR
`
`Notes and soumes:
`
`EX2117: IMS Health, National Prescriptions Audit.
`
`

`
`Attachment B-8a
`Discounts for Onglyza and Kombiglyze XR
`
`Product
`
`Measure
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`Total
`
`Onglyza
`
`Kombiglyze XR
`
`Gross revenue
`Net adjustment
`Managed market discount
`Net revenue
`Managed market discount
`Adjustment share of gross
`Gross revenue
`Net adjustment
`Managed market discount
`Net revenue
`Managed market discount
`Adjustment share of gross
`
`$
`$
`$
`$
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`10.7%
`n/a
`n/a
`n/a
`n/a
`n/a
`n/a
`
`32.3%
`$
`$
`$
`$
`
`33.4%
`
`36.8%
`
`35.0%
`
`54.5%
`
`65.6%
`
`46.2%
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`26.3%
`
`33.2%
`
`37.3%
`
`37.6%
`
`52.6%
`
`57.0%
`
`45.9%
`
`Notes and sources:
`EX1035: AstraZeneca AB v. Aurobindo, et al. , PTX2344 (Hofmann Report).
`I understand that Dr. Meyer does not disagree with any calculations from the Hofmann Report, that she has testified that Exhibit A of the Hofmann report details
`the discounting and managed marketing discounts at BMS and AstraZeneca after the launch of the Onglyza family of products, and specifically confirmed that she
`did not dispute the 58% Onglyza discounting percentage she was asked about during her cross-examination.
`EX1029: AstraZeneca AB v. Aurobindo, et al. , Trial Transcript 442:4-443:5.
`
`Attachment B-8a
`Page 10 of 14
`
`

`
`Attachment B-8b
`
`Notes and sources:
`Attachment B-8a
`
`Attachment B-8b
`Page 11 of 14
`
`

`
`Attachment B-9
`Novartis Net Sales Adjustment
`
`Measure
`
`Gross sales
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`Total
`
`
`
`33,010$
`
`
`
`36,400$
`
`
`
`40,004$
`
`
`
`39,912$
`
`
`
`40,188$
`
`
`
`39,529$
`
`
`
`37,853$
`
`
`
`266,896$
`
`Adjustment to net sales
`
`
`
`(4,723)$
`
`
`
`(6,094)$
`
`
`
`(7,496)$
`
`
`
`(7,759)$
`
`
`
`(7,974)$
`
`
`
`(7,739)$
`
`
`
`(7,408)$
`
`
`
`(49,193)$
`
`Net sales
`
`
`
`28,287$
`
`
`
`30,306$
`
`
`
`32,508$
`
`
`
`32,153$
`
`
`
`32,214$
`
`
`
`31,790$
`
`
`
`30,445$
`
`
`
`217,703$
`
`Net sales adjustment
`
`-14.3%
`
`-16.7%
`
`-18.7%
`
`-19.4%
`
`-19.8%
`
`-19.6%
`
`-19.6%
`
`-18.4%
`
`Notes and sources:
`Figures are in millions of USD.
`Similar information not available for Merck (sitagliptin).
`2009-2011: EX1047: Novartis, Form 20-F, 2011, at 121.
`2012-2013: EX1049: Novartis, Annual Report, 2013, at 166.
`2014-2015: EX1051: Novartis, Annual Report, 2015, at 159.
`
`Attachment B-9
`Page 12 of 14
`
`

`
`Attachment B-10a
`Share of Voice and Prescription Shares Among DDP4 Inhibitors
`
`Product
`
`Measure
`
`Promotional
`Spending
`(millions)
`
`Share of voice
`
`Prescriptions
`(thousands)
`
`Market share
`
`Onglyza
`Kombiglyze XR
`Januvia Family
`Tradjenta Family
`Nesina Family
`Total
`Onglyza
`Kombiglyze XR
`Januvia Family
`Tradjenta Family
`Nesina Family
`Total
`Onglyza
`Kombiglyze XR
`Januvia Family
`Tradjenta Family
`Nesina Family
`Total
`Onglyza
`Kombiglyze XR
`Januvia Family
`Tradjenta Family
`Nesina Family
`Total
`
`2009
`(Jul - Dec)
`44.1$
`
`
`-$
`
`68.1$
`
`-$
`
`-$
`
`112 2$
`39.3%
`0.0%
`60.7%
`0.0%
`0.0%
`100.0%
`33 9
`
`
`-
`
`4,640 2
`-
`
`
`-
`
`4,674.1
`0.7%
`0.0%
`99.3%
`0.0%
`0.0%
`100.0%
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`128.6$
`
`
`0.5$
`
`180 2$
`
`-$
`
`-$
`
`309.3$
`41.6%
`0 2%
`58.3%
`0.0%
`0.0%
`100.0%
`678 2
`
`
`0.1
`
`9,847.3
`
`-
`
`-
`
`10,525.6
`6.4%
`0.0%
`93.6%
`0.0%
`0.0%
`100.0%
`
`85.5$
`
`
`54.1$
`
`186.5$
`
`77.1$
`
`-$
`
`403.1$
`21.2%
`13.4%
`46.3%
`19.1%
`0.0%
`100.0%
`1,480.0
`
`
`372.3
`
`10,986.5
`
`98.7
`
`-
`
`12,937.6
`11.4%
`2.9%
`84.9%
`0.8%
`0.0%
`100.0%
`
`65.8$
`
`
`38 2$
`
`197.1$
`
`140 9$
`
`-$
`
`442.0$
`14.9%
`8.6%
`44.6%
`31.9%
`0.0%
`100.0%
`
`1,909.5
`
`899.5
`
`12,633.6
`
`654.1
`
`-
`
`16,096.8
`11.9%
`5.6%
`78.5%
`4.1%
`0.0%
`100.0%
`
`55.0$
`
`
`33.1$
`
`188.6$
`
`110.0$
`
`18.4$
`
`405.1$
`13.6%
`8 2%
`46.6%
`27.2%
`4.5%
`100.0%
`
`1,816.3
`
`971.7
`
`12,650.4
`
`1,435.9
`
`15.6
`
`16,889.9
`10.8%
`5.8%
`74.9%
`8.5%
`0.1%
`100.0%
`
`35.7$
`
`
`11.1$
`
`260.5$
`
`97.6$
`
`25.4$
`
`430.3$
`8.3%
`2.6%
`60.5%
`22.7%
`5 9%
`100.0%
`
`1,740 9
`
`927 2
`
`12,979.3
`
`1,879.1
`
`49.1
`
`17,575.6
`9.9%
`5.3%
`73.8%
`10.7%
`0.3%
`100.0%
`
`2015
`(Jan - Jul)
`
`14.6$
`5.0$
`
`
`144.0$
`
`33 9$
`
`11.1$
`
`208.6$
`7.0%
`2.4%
`69.1%
`16.3%
`5.3%
`100.0%
`
`897 2
`
`491.5
`
`7,703.5
`
`1,447.9
`
`43 2
`
`10,583.3
`8.5%
`4.6%
`72.8%
`13.7%
`0.4%
`100.0%
`
`Total
`(2009-2015)
`
`429.3$
`
`141 9$
`
`1,225.0$
`
`459.5$
`54 9$
`
`
`2,310.6$
`18.6%
`6.1%
`53.0%
`19.9%
`2.4%
`100.0%
`
`8,556.0
`
`3,662 2
`
`71,440 9
`
`5,515.7
`
`108.0
`
`89,282.8
`9.6%
`4.1%
`80.0%
`6.2%
`0.1%
`100.0%
`
`Total
`(2011-2015)
`256.7$
`
`
`141.4$
`
`976.7$
`
`459.5$
`
`54 9$
`
`1,889.1$
`13.6%
`7.5%
`51.7%
`24.3%
`2 9%
`100.0%
`7,843 9
`
`
`3,662 2
`
`56,953.4
`5,515.7
`
`
`108.0
`
`74,083 2
`10.6%
`4.9%
`76.9%
`7.4%
`0.1%
`100.0%
`
`Notes and sources:
`EX2117: IMS Health, National Prescriptions Audit.
`EX2119: IMS Health, Integrated Promotional Services.
`
`Attachment B-10a
`Page 13 of 14
`
`

`
`Attachment B-10b
`
`Chart of Share of Voice and Prescription Shares for Onglyza and Kombiglyze XR
`
`20.0%
`
`18.0%
`
`Launch through Jul 2015
`
`16.0%
`
`14.0%
`
`12.0%
`
`10.0%
`
`8.0%
`
`6.0%
`
`4.0%
`
`2.0%
`
`0.0%
`
`Onglyza
`
`Kombiglyze XR
`
`Year
`
`I SOV
`
`I Market Share
`
`Notes and sources:
`
`Attachment B-10a
`
`EX2117: IMS Health, National Prescriptions Audit.
`
`EX2119: IMS Health, Integrated Promotional Services.